Home therapy with porcine factor VlllC was safe and effective when administered to five hemophilic patients over periods of 8 %. 6. 4, 3%. and 2 years. No significant transfusion reactions occurred. Before treatment with porcine factor VIIIC, all five had high-level, high-responding anti-human VlllC inhibitors initially lacking anti-porcine factor VlllC activity. Although specific anti-porcine VlllC inhibitors arose in all patients, these were generally transient. and only one patient became refractory to treatment. We believe that porcine factor VlllC is the treatment of choice in patients whose inhibitors do not cross-react. All IRCULATING ANTIBODIES to factor VIIIC (inhib-
very variable and may change after treatment, but averages 15% to 25%.8,9,'5 Reactions occur in only a small percentage of patients, and are usually minor. Thrombocytopenia rarely accompanies treatment .8*93 ' The potential side effects of porcine factor VIIIC have discouraged clinicians from using it in a home-care setting, and it is usually used under hospital supervision. We present data from five patients which demonstrate that a subgroup of inhibitor patients can be identified in whom prolonged home therapy with porcine VIIIC is both successful and safe, and can result in apparent immune tolerance with loss of inhibitor to human factor VIIIC.
PATIENTS AND METHODS
Anti-human factor VIIIC inhibitor activity was measured using the Bethesda Methodi6 and pooled normal plasma. Anti-porcine VIIIC inhibitor activity was measured using the Bethesda Method and a porcine concentrate (Hyate:C, Speywood Laboratories) reconstituted in hemophilic plasma.
Factor VI11 clotting activity was measured using a one-stage method in three centers" and a two-stage method in two," with a pooled normal human plasma standard calibrated against national standards.
Human immunodeficiency virus (HIV) antibody was detected in 1985 and 1986 by radioimmunoassay, but later by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blotting.
T-cell subsets were estimated by flow cytometry. Five patients with severe hemophilia-A (VIIIC less than 0.01 U/mL) from centers in England and France were regularly treated with porcine VIIIC (Hyate:C, Speywood Laboratories) for between 2 and 8% years. These patients were selected for regular treatment with porcine VIIIC because they all had high-responding VIIIC inhibitors precluding satisfactory replacement therapy with human VIIIC, and because their factor VI11 inhibitors were found to lack measurable cross-reactivity to porcine VIIIC.
Porcine VIIIC was administered under close hospital supervision for the first few weeks or months. When no significant treatmentrelated problems were encountered, the treatment was given on an outpatient basis, and then as self-administered home therapy. The treatment regimes used varied according to the frequency of hemarthroses and the personal preference of the clinician. The three patients with most frequent hemarthroses were treated with 20 to 60 U/kg every second day, and the two with less frequent hemarthroses with 20 U/kg on demand.
This 35-year-old patient developed a factor VI11 inhibitor at the age of 4 years that reached a peak of 28 Bethesda Units (BU) during adolescence. He was subsequently treated with factor VI11 concentrate combined with plasmapheresis, prothrombin Treatment with porcine VIIIC began in October 1980 when his inhibitor was found to lack cross-reactivity to porcine VIIIC. He has been treated almost exclusively with this product since that time, and has used no blood products of human origin since 1984. He uses 20 U/kg every second day for prophylaxis, and 40 U/kg for hemarthroses, and his clinical response has always been excellent. Consequently, he has been able to have remedial surgery, resulting in a considerable reduction in pain, and improvement in mobility and work pattern. No significant reactions or thrombocytopenia have been observed. He is anti-HIV seronegative on repeated testing.
This 32-year-old patient has been confined to a wheelchair by hemophilic arthropathy from the age of 8. An anti-human VIIIC inhibitor of 18 BU was detected when he was 15 years old. He was treated irregularly with human factor VIIIC until 1977 when regular treatment with FEIBA prothrombin complex concentrate began. This treatment was ineffective.
In October 1980 his anti-human inhibitor increased to 10 BU after the administration of 500 U of human VIIIC for an ankle bleed. Because no cross-reactivity with porcine VIIIC could be demonstrated at this time, treatment on demand with porcine VIIIC began. His clinical response to 20 U/kg has been consistently excellent and he continued on home therapy, treating his hemarthroses exclusively with porcine VIIIC approximately twice a month over the next 6 years. His inhibitor having disappeared, regular treatment with human VIIIC resumed in 1986. He remains anti-HIV seronegative on repeated testing.
This 22-year-old patient developed an inhibitor at age 7. Treatment with human factor VI11 continued intermittently, but was not very effective. He became disabled with severe painful arthropathy affecting his left hip, both knees, and both ankles, and he began to abuse dihydrocodein. He became infected with HIV during 1984.
In March 1985 he suffered a fractured femur requiring internal fixation, and was treated for 10 days with human VIIIC. This was associated with a rapid anamnestic increase of his anti-human VIIIC inhibitor to 56 BU, with transfusion reactions to human factor VI11 concentrate of increasing severity culminating in a life-threatening anaphylactic reaction on the 10th day of treatment. Therefore, human VIIIC was discontinued, and he has been treated exclusively with porcine VIIIC ever since.
Hemarthroses were initially treated with 50 U/kg of porcine VIIIC because presentation to hospital was usually delayed. After 2 years without any treatment-related problems, home therapy was established. Porcine VIIIC, 20 U/kg, has been found to be adequate, now that his hemarthroses are treated promptly. Therefore, the initiation of home therapy has resulted in considerable financial savings. His joint pain has been much reduced, and he has become fully mobile and far more independent. He no longer abuses analgesics.
Patient 4. This 15-year-old patient developed a high-responding anti-human VIIIC inhibitor increasing to 50 BU at age 5. Treatment with both FEIBA and prothrombin complex concentrates were relatively ineffective, and treatment with human factor VIIIC was always associated with a brisk anamnestic response. By age 10 he was largely confined to a wheelchair by severe hemophilic arthropathy, and suffered knee hemarthroses three times a week. He was able to attend school only 1 day in 3. Synoviorthesis of his knee with osmic acid was attempted in 1983 with little success. He became HIVseropositive during 1983.
In January 1984 regular prophylactic treatment with 50 to 60
Patient 2.
Patient 3.
U/kg porcine VIIIC every second day began in an attempt to improve his quality of life. A 10-fold reduction in the frequency of his hemarthroses resulted, and he was gradually able to regain mobility. Regular treatment with human VIIIC resumed in 1987. This 17-year-old patient was 6 years old when his inhibitor was first detected. Factor VIIIC treatment continued intermittently until the late 1970s when treatment with Autoplex (Baxter Travenol, Glendale, CA) or FEIBA (Immuno, Vienna, Austria) prothrombin complex concentrates in doses of up to 30,000 U/mo began. This failed to control his bleeding or halt the progression of his arthropathy, and human VIIIC precipitated a brisk anamnestic response. It was decided to try treatment with porcine VIIIC.
Prophylaxis with 50 U/kg of porcine VIIIC every second day began in November 1983. Although a specific anti-porcine inhibitor arose soon after treatment with porcine VIIIC began, the clinical response was good and the frequency of his hemarthroses decreased from 52 in the year before to 13 in the year after prophylaxis began. After 2 years, when the anti-porcine VIIIC inhibitor level reached 6 BU, the patient became refractory to treatment. Porcine VIIIC was discontinued, and regular treatment with human VIIIC restarted. The patient became HIV-seropositive in 1983, shortly before starting porcine VIIIC.
Patient 5.

RESULTS
No significant reactions were encountered with porcine VIIIC. Mild pyrexial reactions and a transient modest decrease in platelet count of between 30 and 40 x 109/L were experienced with occasional earlier batches of concentrate by patients 1 and 2. Thrombocytopenia was not observed.
The administration of porcine factor VIIIC did not cause an anamnestic increase in anti-human VIIIC inhibitor activity in any of our patients (Figs 1 through 5) .
A rapid initial decline in anti-human VIIIC inhibitor activity was observed in all patients during the first few months of therapy. A slower decrease in anti-human VIIIC inhibitor followed, and the inhibitor was undetectable 1 to 4 years after the last treatment with human VIIIC. Patient one showed occasional anamnestic increases in inhibitor level associated with human VIIIC therapy until 1984. He has been treated exclusively with porcine VIIIC since this time, and his inhibitor has been undetectable since 1987.
Anti-porcine VIIIC inhibitor activity arose in all patients (Figs 1 through 5 ). This reached a maximum level of 0.5, 2, 0.6, and 1.3 BU in patients 1 through 4, respectively, and did not compromise their clinical responses. These inhibitors were transient in patients 1 and 3 but disappeared more slowly, over 2 to 3 years, in patients 3 and 4 despite continued therapy with porcine VIIIC. Remarkably, patient 5 developed an anti-porcine VIIIC inhibitor lacking cross-reactivity to human VIIIC soon after starting porcine VIIIC. This reached a maximum level of 6 BU after 2 years, causing him to become refractory to porcine VIIIC. Because he had lost his original anti-human VIIIC inhibitor it was possible to resume regular treatment with human VIIIC. This did not provoke an anamnestic response, and his anti-porcine VIIIC inhibitor gradually disappeared over the next 18 months. Porcine factor VIIIC recovery and half-life, estimated in four patients (1, 2, 4, and 5), reflected inhibitor activity against porcine VIIIC. A half-life of 8 to 9 hours and For personal use only. on September 14, 2017. by guest www.bloodjournal.org From recovery of between 1.5% and 2%/U/kg was observed in all patients at the start of treatment. Recovery and half-life assessed serially in patients 4 and 5 declined to a minimum of l%/U/kg and 4 hours in patient 4, and 0.3%/U/kg and 1 hour in patient 5. Recovery and half-life returned to normal in patient 4 when his anti-porcine VIIIC inhibitor could no longer be detected.
Regular home therapy with human VIIIC was reestablished in three patients (2, 4, and 5), 1 to 3 years after their anti-human VIIIC inhibitor had last been detected. Regular treatment with human VIIIC has continued for between 2 and 3 years in these patients, without any recurrence of anti-human VIIIC inhibitor activity (Figs 2,4 , 5). Patients 4 and 5 are HIV-seropositive. Two patients (1 and 3) have not been rechallenged with human VIIIC because they refuse treatment with human factor VIIIC.
Two patients (1 and 2) have remained anti-HIV seronegative on repeated testing. Patients 3, 4, and 5 were infected with HIV before starting porcine VIIIC. Their T4-helper cell counts at the beginning of therapy with porcine VIIIC were 0.8, 1.04, and 0.85 x 109/L respectively, and 0.15 and 0.65, in patients 4 and 5 when treatment with human VIIIC was resumed. Although patients 3 and 4 now have mild acquired immunodeficiency syndrome (AIDS)-related complex (ARC), this did not develop until 1988, and patient 5 is asymptomatic. All three maintain protective levels of hepatitis-B surface antibody (HBsAB).
DISCUSSION
Porcine factor VIIIC was well-tolerated by five patients with anti-human factor VIIIC inhibitors lacking measurable cross-reactivity. No significant reactions or thrombocytopenia were observed. This concurs with the results of a recent multi-center trial that reported minor reactions only with 4% of infusions of porcine VIIIC." The low incidence of reactions reported in more recent series may reflect increasing product purity, specific activity having increased from less than 25 U/mg in 1981' to greater than 140 U/mg in 1989. 19 We suspect that the risk of reactions with current preparations of porcine VIIIC has been overstated.
Although our patients all developed anti-porcine VIIIC inhibitors at some stage, these were transient in four, despite continued treatment with porcine VIIIC. This suggests that they had become tolerant of porcine VIIIC. The induction of immune tolerance in patients with anti-porcine VIIIC inhibitors probably follows the same principles as the induction of immune tolerance in patients with anti-human VIIIC inhibitors by repeated exposure to human factor VIIIC. 3910'12 No measurable anamnestic increase in anti-human VIIIC inhibitor activity followed the use of porcine VIIIC during 2 to 8% years of regular treatment, and the inhibitor disappeared in all patients. An anamnestic increase in anti-human VIIIC inhibitor is reported to follow between 20% and 27% of infusions of porcine VIIIC,6,8*149'5 but may be less likely to occur in the 10% to 20% of patients reported to have inhibitors with little or no affinity for porcine VIIIC.8*9.15
The failure of three of these patients to mount an anamnestic response when rechallenged with human VIIIC suggests that they have become tolerant of human VIIIC. This state of immune tolerance, or specific immune unresponsiveness, has probably arisen as a result of treatment with porcine VIIIC, since these patients all had high-responding inhibitors before starting porcine VIIIC. Tolerance develops for specific antigenic determinants and not particular antigens. Therefore, tolerance to one antigen may be induced by administration of immunogenic doses of a second antigen sharing the epitope to which the subject had originally been sensitized. Porcine VIIIC may have induced tolerance to human VIIIC in this way, and may be a better tolerogen than human VIIIC in some patients because it is less immunogeni~?.'~.'~ Indeed, immune tolerance may have been difficult to achieve conventionally using human VIIIC in our patients, since tolerance is only achieved in between 30% and 50% of patients with high-responding inhibitors often after many months of treatment.3*'w'3 Porcine VIIIC may have a limited role in the induction of tolerance in patients with highresponding factor VIIIC inhibitors lacking cross-reactivity.
Although the unit cost of porcine VIIIC is twice that of intermediate-purity human VIIIC and similar to that of immunoaffinity-purified VIIIC, it is a cost-effective alternative to the high doses of human factor VIIIC often used to treat inhibitor patients.
Inhibitor loss has been reported in occasional patients with marked abnormalities of B-cell function and AIDS. However, this is not a general observation. It appears to be a feature of full-blown AIDS or severe ARC and has not been reported in asymptomatic patients.*'*'' Two of our patients have remained HIV-seronegative, and none of the three HIV-positive patients had AIDS or ARC when treatment with porcine VIIIC began or when human factor VI11 was reintroduced. Continued B-cell competence in these three patients is suggested by the maintenance of protective levels of hepatitis-B surface antibody and the development of specific anti-porcine VIIIC inhibitors. Therefore, HIV infection is unlikely to account for the loss of inhibitor or development of immune tolerance in these patients.
A group of inhibitor patients can be identified by their lack of cross-reactivity to porcine VIIIC in whom prolonged home therapy with this product is safe and effective and may be associated with inhibitor loss and the development of immune tolerance. Although close monitoring of the early phases of treatment is clearly desirable, we would consider porcine VIIIC to be the treatment of choice for inhibitor patients with little or no cross-reactivity.
